Serum Lipoprotein (a) Levels in Patients with First Unprovoked Venous Thromboembolism is not Associated with Subsequent Risk of Recurrent VTE

M. A. Rodger, G. Le Gal, Marc Carrier, M. T. Betancourt, S. R. Kahn, P. S. Wells, D. A. Anderson, K. Lacut, I. Chagnon, S. Solymoss, M. Crowther, A. Perrier, Richard H White, L. Vickars, T. Ramsay, M. J. Kovacs

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: Case-control studies suggest that elevated lipoprotein (a) (Lp(a)) is a risk factor for first venous thromboembolism (VTE). Lp(a) has not been prospectively investigated as a possible risk factor for recurrent VTE in first unprovoked VTE patients. We sought to determine if serum Lp(a) levels in patients with unprovoked VTE who discontinue anticoagulants after 5 to 7 months of therapy predict VTE recurrence in a prospective cohort study. Materials and Methods: Serum Lp(a) measurements were obtained from 510 first unprovoked VTE patients treated for 5 -7 months with anticoagulants in a 12 center study. Patients were subsequently followed for a mean of 16.9 months (SD ± 11.2) for symptomatic VTE recurrence which was independently adjudicated with reference to baseline imaging. Results: There was no significant association between Lp(a) as a continuous variable and recurrent VTE nor in gender stratified subgroups. No statistically significant differences were observed in the median Lp(a) concentrations between patients who recurred and those who did not recur (median (interquartile range): 0.09 g/L (0.17) versus 0.06 g/L (0.11) respectively; p = 0.15). The Lp(a) cut-off point of 0.3 g/L was not significantly associated with recurrent VTE for the overall population nor in gender stratified subgroups. Conclusions: Elevated serum Lp(a) does not appear to be associated with recurrent VTE in patients with history of first unprovoked VTE and may not play a role in identifying patients with unprovoked VTE at high risk of recurrence. There was no optimal predictive threshold for the overall population or for sex sub-groups and Lp(a) ≥ 0.3 g/L was not a significant predictor of recurrent VTE.

Original languageEnglish (US)
Pages (from-to)222-226
Number of pages5
JournalThrombosis Research
Volume126
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Lipoprotein(a)
Venous Thromboembolism
Serum
Recurrence
Anticoagulants
Population
Case-Control Studies
Cohort Studies

Keywords

  • Anticoagulants
  • Cohort
  • Lipoprotein a
  • Risk factor
  • Venous thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Serum Lipoprotein (a) Levels in Patients with First Unprovoked Venous Thromboembolism is not Associated with Subsequent Risk of Recurrent VTE. / Rodger, M. A.; Le Gal, G.; Carrier, Marc; Betancourt, M. T.; Kahn, S. R.; Wells, P. S.; Anderson, D. A.; Lacut, K.; Chagnon, I.; Solymoss, S.; Crowther, M.; Perrier, A.; White, Richard H; Vickars, L.; Ramsay, T.; Kovacs, M. J.

In: Thrombosis Research, Vol. 126, No. 3, 09.2010, p. 222-226.

Research output: Contribution to journalArticle

Rodger, MA, Le Gal, G, Carrier, M, Betancourt, MT, Kahn, SR, Wells, PS, Anderson, DA, Lacut, K, Chagnon, I, Solymoss, S, Crowther, M, Perrier, A, White, RH, Vickars, L, Ramsay, T & Kovacs, MJ 2010, 'Serum Lipoprotein (a) Levels in Patients with First Unprovoked Venous Thromboembolism is not Associated with Subsequent Risk of Recurrent VTE', Thrombosis Research, vol. 126, no. 3, pp. 222-226. https://doi.org/10.1016/j.thromres.2010.06.007
Rodger, M. A. ; Le Gal, G. ; Carrier, Marc ; Betancourt, M. T. ; Kahn, S. R. ; Wells, P. S. ; Anderson, D. A. ; Lacut, K. ; Chagnon, I. ; Solymoss, S. ; Crowther, M. ; Perrier, A. ; White, Richard H ; Vickars, L. ; Ramsay, T. ; Kovacs, M. J. / Serum Lipoprotein (a) Levels in Patients with First Unprovoked Venous Thromboembolism is not Associated with Subsequent Risk of Recurrent VTE. In: Thrombosis Research. 2010 ; Vol. 126, No. 3. pp. 222-226.
@article{4ca5218fa7544de5ad9124587e510013,
title = "Serum Lipoprotein (a) Levels in Patients with First Unprovoked Venous Thromboembolism is not Associated with Subsequent Risk of Recurrent VTE",
abstract = "Introduction: Case-control studies suggest that elevated lipoprotein (a) (Lp(a)) is a risk factor for first venous thromboembolism (VTE). Lp(a) has not been prospectively investigated as a possible risk factor for recurrent VTE in first unprovoked VTE patients. We sought to determine if serum Lp(a) levels in patients with unprovoked VTE who discontinue anticoagulants after 5 to 7 months of therapy predict VTE recurrence in a prospective cohort study. Materials and Methods: Serum Lp(a) measurements were obtained from 510 first unprovoked VTE patients treated for 5 -7 months with anticoagulants in a 12 center study. Patients were subsequently followed for a mean of 16.9 months (SD ± 11.2) for symptomatic VTE recurrence which was independently adjudicated with reference to baseline imaging. Results: There was no significant association between Lp(a) as a continuous variable and recurrent VTE nor in gender stratified subgroups. No statistically significant differences were observed in the median Lp(a) concentrations between patients who recurred and those who did not recur (median (interquartile range): 0.09 g/L (0.17) versus 0.06 g/L (0.11) respectively; p = 0.15). The Lp(a) cut-off point of 0.3 g/L was not significantly associated with recurrent VTE for the overall population nor in gender stratified subgroups. Conclusions: Elevated serum Lp(a) does not appear to be associated with recurrent VTE in patients with history of first unprovoked VTE and may not play a role in identifying patients with unprovoked VTE at high risk of recurrence. There was no optimal predictive threshold for the overall population or for sex sub-groups and Lp(a) ≥ 0.3 g/L was not a significant predictor of recurrent VTE.",
keywords = "Anticoagulants, Cohort, Lipoprotein a, Risk factor, Venous thrombosis",
author = "Rodger, {M. A.} and {Le Gal}, G. and Marc Carrier and Betancourt, {M. T.} and Kahn, {S. R.} and Wells, {P. S.} and Anderson, {D. A.} and K. Lacut and I. Chagnon and S. Solymoss and M. Crowther and A. Perrier and White, {Richard H} and L. Vickars and T. Ramsay and Kovacs, {M. J.}",
year = "2010",
month = "9",
doi = "10.1016/j.thromres.2010.06.007",
language = "English (US)",
volume = "126",
pages = "222--226",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Serum Lipoprotein (a) Levels in Patients with First Unprovoked Venous Thromboembolism is not Associated with Subsequent Risk of Recurrent VTE

AU - Rodger, M. A.

AU - Le Gal, G.

AU - Carrier, Marc

AU - Betancourt, M. T.

AU - Kahn, S. R.

AU - Wells, P. S.

AU - Anderson, D. A.

AU - Lacut, K.

AU - Chagnon, I.

AU - Solymoss, S.

AU - Crowther, M.

AU - Perrier, A.

AU - White, Richard H

AU - Vickars, L.

AU - Ramsay, T.

AU - Kovacs, M. J.

PY - 2010/9

Y1 - 2010/9

N2 - Introduction: Case-control studies suggest that elevated lipoprotein (a) (Lp(a)) is a risk factor for first venous thromboembolism (VTE). Lp(a) has not been prospectively investigated as a possible risk factor for recurrent VTE in first unprovoked VTE patients. We sought to determine if serum Lp(a) levels in patients with unprovoked VTE who discontinue anticoagulants after 5 to 7 months of therapy predict VTE recurrence in a prospective cohort study. Materials and Methods: Serum Lp(a) measurements were obtained from 510 first unprovoked VTE patients treated for 5 -7 months with anticoagulants in a 12 center study. Patients were subsequently followed for a mean of 16.9 months (SD ± 11.2) for symptomatic VTE recurrence which was independently adjudicated with reference to baseline imaging. Results: There was no significant association between Lp(a) as a continuous variable and recurrent VTE nor in gender stratified subgroups. No statistically significant differences were observed in the median Lp(a) concentrations between patients who recurred and those who did not recur (median (interquartile range): 0.09 g/L (0.17) versus 0.06 g/L (0.11) respectively; p = 0.15). The Lp(a) cut-off point of 0.3 g/L was not significantly associated with recurrent VTE for the overall population nor in gender stratified subgroups. Conclusions: Elevated serum Lp(a) does not appear to be associated with recurrent VTE in patients with history of first unprovoked VTE and may not play a role in identifying patients with unprovoked VTE at high risk of recurrence. There was no optimal predictive threshold for the overall population or for sex sub-groups and Lp(a) ≥ 0.3 g/L was not a significant predictor of recurrent VTE.

AB - Introduction: Case-control studies suggest that elevated lipoprotein (a) (Lp(a)) is a risk factor for first venous thromboembolism (VTE). Lp(a) has not been prospectively investigated as a possible risk factor for recurrent VTE in first unprovoked VTE patients. We sought to determine if serum Lp(a) levels in patients with unprovoked VTE who discontinue anticoagulants after 5 to 7 months of therapy predict VTE recurrence in a prospective cohort study. Materials and Methods: Serum Lp(a) measurements were obtained from 510 first unprovoked VTE patients treated for 5 -7 months with anticoagulants in a 12 center study. Patients were subsequently followed for a mean of 16.9 months (SD ± 11.2) for symptomatic VTE recurrence which was independently adjudicated with reference to baseline imaging. Results: There was no significant association between Lp(a) as a continuous variable and recurrent VTE nor in gender stratified subgroups. No statistically significant differences were observed in the median Lp(a) concentrations between patients who recurred and those who did not recur (median (interquartile range): 0.09 g/L (0.17) versus 0.06 g/L (0.11) respectively; p = 0.15). The Lp(a) cut-off point of 0.3 g/L was not significantly associated with recurrent VTE for the overall population nor in gender stratified subgroups. Conclusions: Elevated serum Lp(a) does not appear to be associated with recurrent VTE in patients with history of first unprovoked VTE and may not play a role in identifying patients with unprovoked VTE at high risk of recurrence. There was no optimal predictive threshold for the overall population or for sex sub-groups and Lp(a) ≥ 0.3 g/L was not a significant predictor of recurrent VTE.

KW - Anticoagulants

KW - Cohort

KW - Lipoprotein a

KW - Risk factor

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=77956268733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956268733&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2010.06.007

DO - 10.1016/j.thromres.2010.06.007

M3 - Article

C2 - 20580413

AN - SCOPUS:77956268733

VL - 126

SP - 222

EP - 226

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 3

ER -